Investor Presentation - January 2016
Mangalam Drugs & Organics Ltd has informed BSE regarding "Investor Presentation - January 2016".22-02-2016
Investor Presentation - January 2016
Mangalam Drugs & Organics Ltd has informed BSE regarding "Investor Presentation - January 2016".Shareholding for the Period Ended December 31, 2015
Mangalam Drugs & Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click hereCorrigendum to Financial Results for Dec 31, 2015
With respect to the earlier Announcement dated January 14, 2016, regarding Financial Results for December 31, 2015, Mangalam Drugs & Organics Ltd has informed BSE that there is a typing error in Notes Section (Note No 4) which are enclosing as a Corrigendum.Financial Results & Limited Review Report for Dec 31, 2015 (Standalone)
Mangalam Drugs & Organics Ltd has informed BSE about the Standalone Financial Results & a copy of the Limited Review Report for the period ended December 31, 2015.Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Mangalam Drugs & Organics Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Board Meeting on Jan 14, 2016
Mangalam Drugs & Organics Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on January 14, 2016, inter alia, to consider and take on record the following:1. To consider and take on record the Unaudited Financial Results for the quarter and nine months ended December 31, 2015.2. To appoint the Internal Auditor of the Company for the financial year 2015-2016;...Mangalam Drugs locked lower circuit for 10 straight trading sessions
In past two-weeks, the stock tanked 40% to Rs 265 from its 52-week high of Rs 442 touched on December 8.Authorised KMPs to determine materiality of events/information
Mangalam Drugs & Organics Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
JB Pharma LLP has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Outcome of Board Meeting
Mangalam Drugs & Organics Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 16, 2015, inter alia, has transacted the following business:- Approval of allotment of 12,00,000 Equity Shares on conversion of 12,00,000 Share warrants of Rs. 10/- each at a premium of Rs. 55/- per share out of the total 26,50,000 Warrants allotted to promoter group on preferential basis, upon the receipt of balance consideration amount on it.